The patentability of biotech inventions should meet substantive requirements such as novelty, inventive step and industrial applicability, but EPO developments suggest that formalities are increasingly important.
Advocate-General Verica Trstenjak has delivered an opinion in the case of Neurim Pharmaceuticals that, if followed by the Court of Justice of the EU, will profoundly liberalise the law governing SPCs in Europe.
The European life sciences industry has a long history. Many of the major players trace their roots to before the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions.
Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled.
The traditional business model for a new drug relies on a substantial period of market exclusivity to recoup extensive research and development costs.
Recent European decisions have provided much to think about for practitioners concerned with DNA sequences. Caroline Pallard and Bart Swinkels investigate.
First instance courts in France have adopted controversial interpretations of an important Enlarged Board of Appeal decision, says Stéphane Agasse.
There is a general acceptance that European patent law is complicated, particularly in the area of pharmaceutical inventions. Claire Baldock looks at how the EPO approaches these inventions.
A case before the Court of Justice for the European Union threatens to radically redraw the patent landscape for embryonic stem cells. Ashley Roughton explains.
The European Court of Justice is faced with a crucial decision on stem cell research. Justin Turner QC explains.